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Abstract
AIM
To investigate the impact of histology on outcome in 
advanced oesophageal cancer treated with first-line 
fluoropyrimidine-based chemotherapy.
METHODS
Individual patient data were pooled from three ran-
domised phase Ⅲ trials of fluoropyrimidine-based 
chemotherapy ± platinum/anthracycline in patients with 
advanced, untreated gastroesophageal adenocarcinoma 
or squamous cell carcinoma (SCC) randomised between 
1994 and 2005. The primary endpoint was overall survival 
of oesophageal cancer patients according to histology. 
Secondary endpoints were response rates and a toxicity 
composite endpoint.
RESULTS
Of the total 1836 randomised patients, 973 patients (53%) 
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were eligible (707 patients with gastric cancer were 
excluded), 841 (86%) had adenocarcinoma and 132 
(14%) had SCC. There was no significant difference in 
survival between patients with adenocarcinoma and SCC, 
with median overall survivals of 9.5 mo vs 7.6 mo (HR = 
0.85, 95%CI: 0.70-1.03, P  = 0.09) and one-year survivals 
of 38.8% vs  28.2% respectively. The overall response 
rate to chemotherapy was 44% for adenocarcinoma vs 
33% for SCC (P = 0.01). There was no difference in the 
frequency of the toxicity composite endpoint between the 
two groups. 
CONCLUSION
There was no significant difference in survival between 
adenocarcinoma and SCC in patients with advanced 
oesophageal cancer treated with fluoropyrimidine-based 
chemotherapy despite a trend for worse survival and less 
chemo-sensitivity in SCC. Tolerance to treatment was 
similar in both groups. This analysis highlights the unmet 
need for SCC-specific studies in advanced oesophageal 
cancer and will aid in the design of future trials of targeted 
agents.
Key words: Oesophageal cancer; Adenocarcinoma; 
Chemotherapy; Squamous; Pooled analysis
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: There is a lack of published data on differential 
treatment response according to histology in oesophageal 
cancer. This paper shows improved response rates with 
first-line chemotherapy and a trend towards improved 
survival in adenocarcinoma compared to squamous cell 
carcinoma (SCC). It is increasingly recognised that these 
histological subtypes represent discrete disease entities 
with divergent treatment pathways in both the early stage 
and advanced settings. Novel treatments in SCC remain 
sparse and there are few dedicated trials in this subtype. 
This data highlights the poor outcomes seen with che-
motherapy alone and the need for further research, 
particularly for SCC. 
Davidson M, Chau I, Cunningham D, Khabra K, Iveson T, 
Hickish T, Seymour M, Starling N. Impact of tumour histological 
subtype on chemotherapy outcome in advanced oesophageal 
cancer. World J Gastrointest Oncol 2017; 9(8): 333-340  Available 
from: URL: http://www.wjgnet.com/1948-5204/full/v9/i8/333.htm 
DOI: http://dx.doi.org/10.4251/wjgo.v9.i8.333
INTRODUCTION
Oesophageal cancer is the eighth most common 
malignancy worldwide with an estimated 456000 
new cases and 400000 deaths worldwide in 2012, 
ranking it the sixth most common cause of cancer-
related deaths[1]. Despite recent advances in genetic 
and molecular characterisation and the development 
of novel targeted agents survival rates for oesophageal 
carcinoma have changed little for many decades, 
and outcomes for advanced disease remain poor. 
Worldwide, squamous cell carcinoma (SCC) is the 
predominant histological subtype however in North 
America and Northern Europe the incidence of 
oesophageal adenocarcinoma has increased in the 
last 20 years whereas that of SCC has decreased[2,3]. 
This is likely to reflect the distinct aetiological factors 
implicated in the development of the two diseases. 
SCC is strongly correlated with excessive alcohol 
consumption, cigarette smoking and poor socioeconomic 
status whereas adenocarcinoma is associated with 
obesity and gastroesophageal reflux disease (GORD)[3-6]. 
Thus the rise in adenocarcinoma may be in part due 
to changing lifestyle factors in Western populations[3]. 
Genomic technology has been applied to both gastric 
and oesophageal cancer in an effort to improve under-
standing and stratification on a genetic and molecular 
level, with emerging differences in the genetic landscape 
between the two histological subtypes suggesting 
a need for more tailored therapeutic strategies[7,8]. 
Historically however treatment patterns for both subtypes 
have been similar, with many clinical trials evaluating 
chemotherapy conducted since the mid-1990s including 
patients with gastric, oesophageal, or oesophagogastric 
junction (OGJ) cancer, regardless of histology. Similarly, 
studies in early stage oesophageal cancer often include 
both histological subtypes, such as the recent CROSS 
trial evaluating neoadjuvant chemo-radiation. This 
identified disparities in outcome according to histology, 
with a statistically significant overall survival benefit 
seen only in the smaller SCC cohort[9]. 
In the advanced disease setting cisplatin/fluorouracil 
with the possible addition of a third drug - either 
epirubicin or a taxane - is commonly used as a first-line 
chemotherapy, and second-line agents include irinotecan, 
docetaxel and paclitaxel[10,11]. More recently treatment 
patterns have diverged, with the introduction of novel 
molecularly-targeted therapy for gastroesophageal 
adenocarcinomas. Notably effective therapies targeting 
HER2 (trastuzumab) and the vascular endothelial growth 
factor receptor 2 (ramucirumab) are applicable only to 
adenocarcinomas[12-14]. 
Three randomised phase Ⅲ studies of fluoro-
pyrimidine-based combination chemotherapy have 
been published in patients with advanced gastro-
esophageal cancer including oesophageal SCC and 
adenocarcinoma[10,15,16]. In multivariate Cox regression 
analysis histology was not identified as a variable 
impacting on survival, however patients with SCC 
accounted for less than 10% of the patients in each 
trial. Although SCC normally represent a small minority 
of patients enrolled on most clinical trials it is not 
clear what influence histologic subtype exerts on 
response rate or survival duration in patients treated 
with cytotoxic chemotherapy regimens for metastatic 
disease, and SCC has been associated with both worse, 
better or similar outcomes to adenocarcinoma[17-19]. 
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The distinct epidemiological, genetic and molecular 
characteristics of SCC as compared to adenocarcinoma 
could potentially influence response to therapies 
administered in the advanced disease setting. In this 
pooled analysis of the three randomised phase Ⅲ 
studies which included patients with both advanced 
oesophageal SCC and adenocarcinoma, we aimed to 
evaluate whether there was a differential treatment 
effect according to histology. 
MATERIALS AND METHODS
Patients and treatments
Between 1994 and 2005, 1836 patients were rando-
mised predominantly from the United Kingdom in 
three multi-centre randomised controlled trials of 
fluoropyrimidine-based chemotherapy in patients with 
untreated locally advanced or metastatic carcinoma of 
oesophagus, OGJ, or stomach[10,15,16]. Similar eligibility 
criteria were applied in the three trials; patients had 
histologically confirmed inoperable adenocarcinoma, 
SCC or undifferentiated carcinoma of the oesophagus, 
OGJ or stomach, adequate haematological, renal and 
hepatic function and an Eastern Co-operative Oncology 
Group performance status (PS) of 0-2. Written informed 
consent was obtained from all patients and all three 
studies were approved by the Scientific and Research 
Ethics Committees of the participating institutions. 
The first study randomised 580 patients between 
1995 and 1998 to treatment with ECF [epirubicin 50 
mg/m2 intravenously (IV) and cisplatin 60 mg/m2 IV 
infusion with hydration on day 1 plus 5-FU 200 mg/m2 
per day by protracted venous infusion (PVI)] or MCF 
[mitomycin C (MMC) 7 mg/m2 on day 1 every six 
weeks, cisplatin 50 mg/m2 IV day 1 and PVI-5-FU 300 
mg/m2 per day][15]. The second study randomised 254 
patients between 1994 and 2001 to PVI 5-FU (300 mg/
m2 per day) or the same dose of PVI 5-FU plus MMC (7 
mg/m2 every six weeks)[16]. The third study conducted 
randomised 1002 patients between 2000 and 2005 to 
ECF, ECX (X denotes capecitabine given at a dose of 
625 mg/m2 twice a day continuously), EOF (O denotes 
oxaliplatin 130 mg/m2 on day 1 every three weeks 
replacing cisplatin) and EOX[10]. 
A maximum of 8 cycles of chemotherapy (24 wk) 
with response assessment computed tomography 
(CT) scans at 12 and 24 wk was stipulated in the three 
study protocols. Overall survival (OS) was the primary 
outcome measure in these trials and toxicity data was 
recorded at each treatment visit every three weeks. 
Only eligible patients with squamous carcinoma or 
OGJ adenocarcinoma who received at least one dose of 
chemotherapy were included in this analysis which was 
based on individual patient data from these trials.
Statistical analysis
OS was the primary endpoint of this pooled analysis 
and was calculated from the date of randomisation until 
death from any cause, or censored at the date of last 
follow-up for surviving patients according to the Kaplan-
Meier method. Survival analyses were performed on 
the eligible population and compared between patients 
with SCC and adenocarcinoma using the log rank test. 
Multivariate survival analysis was performed using Cox 
proportional hazard model and stratified for treatment 
centres. The following factors were included: Histology, 
gender, primary site (oesophagus vs OGJ), liver or 
peritoneal metastases (presence vs absence), serum 
alkaline phosphatase (< 100 U/L vs ≥ 100 U/L) and 
performance status (0-1 vs 2) based on previously-
identified prognostic factors in advanced OG cancer[20,21], 
as well as treatment arm and trial. 
Objective response rates between SCC and adeno-
carcinoma were compared using χ 2 test. A chemo-
therapy-specific toxicity composite endpoint (TCE) 
was constructed as a surrogate for undesirable cycto-
toxic-related toxicities. TCE was defined as the first 
occurrence of grade 3 or 4 diarrhoea, neutropenia, 
febrile neutropenia, fever, infection, nausea and 
vomiting or grade ≥ 2 renal or neurotoxicity. TCE was 
compared between the two histological subtypes using 
χ 2 test. Time to TCE was compared between SCC and 
adenocarcinoma using log rank test.
Two-sided P value of less than 0.05 were considered 
significant for the overall survival endpoint, and 95%CI 
quoted. Analyses were performed using SPSS package 
version 23 (SPSS Inc, Chicago, IL, United States). 
RESULTS
Patient characteristics
Of the 1836 patients randomised to the three trials, 973 
patients (53%) were eligible for this pooled analysis as 
indicated in Figure 1. Seven hundred and seven of the 
1836 patients (39%) were excluded due to the primary 
tumour origin being gastric. Of the 973 eligible patients 
841 (86%) had adenocarcinoma and 132 (14%) had 
SCC. Baseline patient characteristics are shown in 
Table 1. These were broadly balanced between the two 
histological sub-types except that predictably a greater 
proportion of adenocarcinoma occurred at the OGJ with 
metastases to the liver/peritoneum, and there were 
more males with adenocarcinoma. 
Survival
At the time of the data cut-off, 863 of the 973 patients 
(88%) had died and the median follow-up for surviving 
patients was 19 mo. The median survival for the whole 
cohort of 973 eligible patients was 9.4 mo (95%CI: 
8.82-9.99). One year survival was 37.3% (95%CI: 
37.27-37.33) and 2 year survival was 13.5% (95%CI: 
13.48-13.52). There was no significant difference 
in survival between patients with adenocarcinoma 
and SCC, with median OS of 9.5 mo vs 7.6 mo (HR 
= 0.85, 95%CI: 0.70-1.03, P = 0.09), although the 
curves did appear to separate between 6 mo to 2 
Davidson M et al . Oesophageal cancer histology and chemotherapy response
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years suggestive of a poorer survival for SCC during 
this period (Figure 2A). One and two year survival 
figures for adenocarcinoma were 38.8% (95%CI: 
38.77-38.83) and 13.6% (95%CI: 13.57-13.63) 
respectively and for SCC were 28.2% (95%CI: 
28.12-28.28) and 12.3% (95%CI: 12.24-12.36). 
When considering “true” oesophageal cancer patients 
only and excluding those with junctional tumours, 
there was again no significant difference in survival 
between patients with adenocarcinoma (n = 438) and 
SCC (n = 117), with median OS of 9.5 mo vs 7.7 mo 
(HR = 0.91, 95%CI: 0.73-1.13, P = 0.38) (Figure 
2B). In multivariate analysis, previously identified 
known prognostic factors of performance status, liver/
peritoneal metastases and alkaline phosphatase were 
all significant. Histology and site of primary tumour 
were not shown to be significant prognostic factors. 
For effect of treatment received there was a significant 
association of treatment within trial 2[16]-which did not 
incorporate a platinum component into either treat-
ment arm-with poorer outcome (Table 2). 
Response and toxicity
The objective response rate to chemotherapy (Table 
3) was significantly higher for patients with adeno-
carcinoma compared to SCC (44% vs 33%, P = 0.01). 
A greater proportion of patients with SCC compared to 
adenocarcinoma progressed during chemotherapy (29% 
vs 19%, P = 0.01) and the proportion of patients with 
stable disease was similar for both histological subtypes. 
There was no difference in the proportion of patients 
experiencing the toxicity composite endpoint (TCE) for 
adenocarcinoma as compared to SCC (45% vs 44%, P 
= 0.77) (Table 3). Similarly there was no difference in 
the time to development of TCE (Figure 3) between the 
histological subtypes (HR = 0.98, 95%CI: 0.74-1.29, P 
= 0.9).
DISCUSSION
This study represents the largest pooled analysis of 
differential chemotherapy effects in patients with 
Trial 1[15]
ECF vs  MCF
n  = 580
Adeno n  = 475
SCC n  = 40 
Trial 2[16]
PVI 5-FU vs  PVI 5-FU + MMC
n  = 254
Adeno n  = 227
SCC n  = 11
Trial 3[10]
ECF vs  ECX, EOF, EOX
n = 1002
Adeno n  = 885
SCC n  = 101
Total randomised 
n  = 1836
Patients excluded from the analysis:
  Gastric carcinoma: n  = 707
  Ineligible or withdrawn before treatment: n  = 42
  Undifferentiated or other histology: n  = 461
  Histology not recorded: n  =  44
  Other: n  = 24
Eligible patients who received ≥ one 
cycle of chemotherapy n  = 973
Adeno
n  = 841
SCC
n = 132
Figure 1  CONSORT diagram indicating the derivation of eligible patients in this analysis. 1Includes carcinoma, undifferentiated carcinoma, adenosquamous 
carcinoma. SCC: Squamous cell carcinoma; PVI: Protracted venous infusion.
Table 1  Patient characteristics n  (%)
Adeno SCC Total
No. of patients 841 132 973
Median age (range)        62 (22-84)        60 (37-77)        61 (22-84)
Gender
  Male 730 (87)   95 (72) 825 (85)
  Female 111 (13)   37 (28) 148 (15)
Performance status1
  0 223 (27)   33 (25) 256 (26)
  1 489 (58)   75 (57) 564 (58)
  2 127 (15)   23 (18) 150 (15)
Sub-site
  Oesophagus 438 (52) 117 (89) 555 (57)
  OGJ 403 (48)   15 (11) 418 (43)
Extent of disease2
  Locally advanced 219 (26)   36 (27) 255 (26)
  Metastatic 622 (74)   95 (72) 717 (74)
Location of metastases
  Liver 340 (46)   46 (35) 386 (40)
  Peritoneum 41 (5)   4 (3)   45 (4.5)
  Lung 136 (16)   18 (14) 154 (16)
1PS unknown or 3 in < 1% of all patients; 2Data was unavailable for one patient 
in the SCC group. SCC: Squamous cell carcinoma; OGJ: Oesophagogastric 
junction.
Davidson M et al . Oesophageal cancer histology and chemotherapy response
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Table 2  Multivariate analyses of overall survival
advanced oesophageal adenocarcinoma and SCC 
undergoing fluoropyrimidine-based chemotherapy 
in randomised phase Ⅲ controlled trials with mature 
survival data. All three analysed trials incorporated a 
fluoropyrimidine in each treatment arm, and two of the 
trials included a platinum agent in each arm. In this 
pooled analysis there was no significant difference in 
overall survival between patients with adenocarcinoma 
compared to those with SCC with median overall 
survivals of 9.5 mo vs 7.6 mo (HR = 0.85, P = 0.09) 
Factors Univariate analysis Multivariate analysis
HR 95%CI P  value HR 95%CI P  value
Overall survival
Histological arm Adenocarcinoma (r) 1.000
SCC 1.196 0.972-1.471    0.089
Sex Female (r) 1.000
Male 0.983 0.807-1.196    0.983
Subsite Oesophagus (r) 1.000
OGJ 0.988 0.853-1.145    0.876
Liver mets No (r) 1.000 1.000
Yes 1.671 1.433-1.948 < 0.001 1.581 1.341-1.863 < 0.001
Peritoneal mets No (r) 1.000 1.000
Yes 2.290 1.583-3.314 < 0.01 2.190 1.503-3.191 < 0.001
ALP < 100 U/I (r) 1.000 1.000
≥ 100 U/I 1.608 1.357-1.908 < 0.001 1.287 1.072-1.544    0.007
Performance score 0-1 (r) 1.000 1.000
2-3 2.140 1.754-2.611 < 0.001 1.703 1.374-2.110 < 0.001
Treatment arm EOX (r) 1.000
EOF 1.122 0.848-1.484    0.420
ECX 1.139 0.862-1.505    0.361
ECF 1.175 0.916-1.506    0.204
MCF 1.176 0.870-1.589    0.291
PVI 5FU + MMC 2.107 1.461-3.040 < 0.001
PVI 5FU 2.132 1.481-3.067 < 0.001
Overall < 0.001
Study Trial 3[10] (r) 1.000 1.000
Trial 1[15] 0.993 0.804-1.228    0.951 1.034 0.830-1.288    0.763
Trial 2[16] 1.850 1.432-2.390 < 0.001 1.736 1.326-2.271 < 0.001
Overall < 0.001 < 0.001
All variables with a P-value of less than 0.2 in univariate analyses were entered into a multivariate model in a forward stepwise manner. r: Reference; mets: 
Metastases; SCC: Squamous cell carcinoma; OGJ: Oesophagogastric junction; PVI: Protracted venous infusion; MMC: Mitomycin C.
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Figure 2  Overall survival. A: Overall survival according to histology (adenocarcinoma = 841 patients, SCC = 132 patients). The HR for death in the adenocarcinoma 
group compared to the SCC group was 0.85 (95%CI: 0.70-1.03, P = 0.09); B: Overall survival according to histology excluding OGJ tumours (adenocarcinoma = 438 
patients, SCC = 117 patients). The HR for death for the adenocarcinoma group compared to the SCC group was 0.91 (95%CI: 0.73-1.13, P = 0.38). SCC: Squamous 
cell carcinoma; OGJ: Oesophagogastric junction.
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respectively. A possible limitation of interpretation of 
this data is the imbalanced distribution of histological 
subtype between oesophageal and OGJ cancers. As 
expected, the proportion of SCC histology was higher 
in the oesophageal only group as compared to the total 
cohort of oesophageal and OGJ patients (21% vs 14%). 
A further analysis excluding OGJ patients however 
also did not show a significant difference in median OS 
between adenocarcinoma and SCC (9.5 mo vs 7.7 mo, 
HR = 0.91, P = 0.38). Histology and site of primary 
tumour were not shown to be predictors of survival in 
multivariate analysis, consistent with previously reported 
prognostic variables in oesophageal and gastric cancer 
based on smaller analyses[20,22,23]. The survival curves 
did appear to separate between 6 mo and 2 years, 
with SCC patients appearing to have worse survival 
during this period, but the curves then overlapped from 
two years onwards. Lack of a statistically significant 
difference in survival in the presence of a trend could 
reflect that this pooled analysis remains underpowered. 
Although the potential for heterogeneity may confound 
interpretation of data from pooled analyses, the 
eligibility criteria for these three trials were similar, 
individual patient data were used to strengthen the 
analysis, treatment arms and trials were incorporated 
in the multivariate analysis and survival outcomes 
from ECF, evaluated in the two largest trials[10,15], were 
consistent. Inclusion of patients with advanced SCC in 
these studies was controversial in terms of potentially 
creating a heterogeneous study population however 
based on the current analysis survival outcomes with 
standard chemotherapy are not significantly different with 
SCC compared to adenocarcinoma, although there may 
be a trend towards worse survival. The only differential 
treatment effect noted was a significant difference in 
objective response rates between adenocarcinoma and 
SCC (44% vs 33% respectively). A greater proportion 
of SCC patients also progressed during treatment (29% 
vs 19%), suggesting that oesophageal SCC may be less 
chemo-sensitive than adenocarcinoma. 
There was no difference in time to development 
of TCE or of the proportion of patients with TCE 
between the two histological sub-types. A difference 
might have been expected given the association of co-
morbid conditions with SCC. However, within clinical 
trials there may be selection bias favouring inclusion of 
fitter patients (patients with a performance status of 2 
comprised only 15% of the pooled patient population 
in this analysis). Although this does potentially limit 
extrapolation of the results of this analysis to patients 
with SCC in the general population this would apply to 
most randomised controlled trials in this disease. 
Application of genomic technology is revealing 
increasing differences between the histological subtypes 
of oesophageal cancer on a genetic and molecular level. 
In an analysis performed by the Cancer Genome Atlas, 
four gastric cancer subtypes have been proposed: 
Tumours positive for Epstein-Barr virus (EBV), micro-
satellite unstable tumours (MSI), genomically stable 
(GS) tumours and tumours with chromosomal instability 
(CIN)[24]. Each subtype was found throughout the 
stomach, but CIN tumours showed elevated frequency 
in the OGJ and cardia. In CIN tumours genomic amp-
lifications of receptor tyrosine kinases such as VEGFA 
and cell cycle mediators such as CCND1 and CDK6 
with potentially relevant clinical implications were found 
with increased frequency. Specific to oesophageal 
adenocarcinomas, a sequencing study of 149 tumours 
by a United States group published in Nature Medicine 
in 2013 confirmed recurrent mutations in known 
cancer-driving genes including TP53, CDKN2A, SMAD4, 
ARID1A and PIK3CA[25]. Similarly, a number of recent 
studies have applied NGS to the study of oesophageal 
SCC, demonstrating recurrent mutations in known 
oncogenic drivers including TP53, NOTCH1, PIK3CA 
and FAT1, as well as amplifications in CCND1 and 
CDKN2A[26]. The cell cycle regulation pathway is one 
of the most consistently altered in oesophageal SCC, 
where mutations are observed at a high frequency and 
are associated with poor prognosis and metastasis[27,28]. 
A recent study has compared the genomic profiles of 71 
SCC and 231 oesophageal adenocarcinomas, focusing 
Table 3  Objective response rates and toxicity composite 
endpoint n  (%)
Adeno SCC
No. of patients 841 132
Complete response 48 (6) 7 (5)
Partial response 323 (38) 36 (27)
Stable disease 224 (30) 35 (27)
Progressive disease 157 (19) 38 (29)
Objective response rate 
(95%CI)
371 (44)
41%-48%
43 (33)
25%-41%
P = 0.01
Toxicity composite endpoint 
(95%CI)
381 (45)
42%-49%
58 (44)
35%-53%
P = 0.77
SCC: Squamous cell carcinoma.
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Figure 3  The time to development of the toxicity composite endpoint 
is shown for patients with adenocarcinoma (n = 841) vs squamous cell 
carcinoma (n = 132). TCE: Toxicity composite endpoint.
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on the identification of therapeutically relevant genomic 
alterations in both groups[8]. Similarly high frequencies 
of clinically relevant genomic alterations were found 
in both histological subtypes; however the profiles 
of genomic alterations in the two diseases differed 
substantially. KRAS and HER2 were more frequently 
altered in adenocarcinoma, while MTOR pathway genes 
(PIK3CA, PTEN) and NOTCH1 were more frequently 
altered in SCC. Exploitation of the molecular differences 
between the two histological sub-types may help direct 
optimal application of targeted therapies in this disease. 
Although our data is historical, the chemotherapy 
landscape for oesophageal cancers has not changed 
significantly in the intervening years. Targeted treat-
ments for oesophageal adenocarcinomas are now in 
routine clinical use and starting to provide tangible 
improvement to patient outcomes, however there 
remains a relative lack of both applied research and 
effective treatments for advanced SCC. Given small 
patient numbers and apparently declining incidence, 
further randomised SCC-specific phase Ⅲ trials of 
systemic therapy in advanced oesophageal cancer 
in Western populations will be challenging. Future 
improvements in outcome are likely to come from 
smaller studies investigating cohorts of patients 
enriched for discrete genetic aberrations, or from the 
use of combination immunotherapeutic approaches. 
Optimising the design of such studies using appropriate 
chemotherapies as either comparators or backbones to 
newer investigative agents requires an understanding 
of differential effectiveness and toxicity of standard 
chemotherapy regimes. This analysis demonstrated 
no significant difference in survival or tolerance to 
chemotherapy between patients with adenocarcinoma 
or SCC. Given the poor outcomes seen with chemo-
therapy it reinforces the need for SCC-specific trials in 
advanced oesophageal cancer.
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